Novartis Leadership In Psoriasis Therapies Could Be Consolidated With New Drug "Cosentyx"
March 22, 2017 at 02:00 AM EDT
The pharma giant Novartis is looking to consolidate its hold on the lead role for new therapies for psoriasis with some remarkable data suggesting the drug could act as a disease modifier for a significant group of patients.